Mixed myeloproliferative and myelodysplastic disorders

Current Hematologic Malignancy Reports

Volumn 2, Issue 1, 2007, Pages 9-12

  Emanuel, Peter D ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BCR ABL PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; JANUS KINASE 2; NEUROFIBROMIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ATYPICAL CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL FEATURE; DISEASE CLASSIFICATION; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKOCYTE COUNT; MIXED MYELODYSPLASTIC MYELOPROLIFERATIVE DISEASE; MYELODYSPLASTIC SYNDROME; NOONAN SYNDROME; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; REVIEW; WORLD HEALTH ORGANIZATION;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC-MYELOPROLIFERATIVE DISEASES; PROGNOSIS; SEX DISTRIBUTION; TRANSLOCATION, GENETIC;

EID: 34250706706     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-007-0002-6     Document Type: Review

References (20)

1. Brunning RD, Bennett JM, Flandrin G, et al.: Myelodys-plastic syndromes. In Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues: World Health Organization Classification of Tumours. Edited by Jaffe ES, Harris NL, Stein H, Vardimann JW. Lyon, France: IARC Press; 2001:61-73.
2. Greenberg P, Cox C, LeBeau MM, et al.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
3. Bennett JM, Catovsky D, Daniel MT, et al.: The chronic myeloid leukemias: guidelines for distinguishing chronic granulocytic leukemia, atypical chronic myeloid and chronic myelomonocytic leukemia: proposals by the French-American-British Cooperative Leukemia Group. Br J Haematol 1994, 87:746-754.
4. Voglova J, Chrobak L, Neuwirtova R, et al.: Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukemia - distinct subgroups or two stages of the same disease? Leuk Res 2001, 25:493-499.
5. Tefferi A, Gilliland G: Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system. Best Tract Res Clin Haematol 2006, 19:365-385. Will this, or some form of it, be the next classification system for the myeloproliferative disorders? Although it is cumbersome, the basis of this system at least incorporates our fast-changing knowledge of the molecular events underlying the chronic myeloid disorders. Many other articles in this particular journal issue also provide very worthwhile reading.
6. Emanuel P, Prchal JT: The molecular basis of polycythemia vera unraveled? The Hematologist: ASH News and Reports 2005, 2(3):1-2.
7. Golub TR, Barker GF, Lovett M, Gilliland DG: Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994, 77:307-316.
8. Onida F, Kantarjian HM, Smith TL, et al.: Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002, 99:840-849.
9. Silverman LR, Demakos EP, Peterson BL, et al.: Randomized controlled trial of azacitidine in patients with myelodysplastic syndrome: a study of the CALGB. J Clin Oncol 2002, 20:2429-2440.
10. Kantarjian H, Issa JP, Rosenfeld CS, et al.: Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106:1774-1780.
11. Kaminskas E, Farrell A, Abraham S, et al.: Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 2005, 11:3604-3608.
12. Elliott MA, Tefferi A, Hogan WJ, et al.: Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Trans 2006, 37:1003-1008.
13. Kantarjian H, Oki Y, Garcia-Manero G, et al.: Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2006, In press.
14. Pinkel D: Differentiating juvenile myelomonocytic leukemia from infectious disease. Blood 1998, 91:365-367.
15. Locatelli F, Noelke P, Zecca M, et al.: Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood 2005, 105:410-419.
16. Emanuel PD: Juvenile myelomonocytic leukemia [review]. Curr Hematol Rep 2004, 3:203-209. This review of juvenile myelomonocytic leukemia provides a more comprehensive account of the pathogenetic mechanisms underlying this disorder than space allows in the present review.
17. Largaespada DA, Brannan CI, Jenkins NA, Copeland NG: Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony-stimulating factor hypersensitivity and chronic myeloid leucemia. Nat Genet 1996, 12:137-143.
18. Bollag G, Clapp DW, Shih S, et al: Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in hematopoietic cells. Nat Genet 1996, 12:144-148.
19. Tartaglia M, Niemeyer CM, Fragale A, et al.: Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003, 34:148-150.
20. Mohi MG, Williams IR, Dearolf CR, et al.: Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell 2005, 7:179-191.